Abstract
Cancer incidence rates in the UK have increased by more than a third over the last four decades, so the likelihood of requiring concurrent chemotherapy and clozapine is increasing. In this situation clinicians are faced with a clinical conundrum: to stop clozapine and risk a psychotic relapse, or to continue clozapine and risk a potentially fatal agranulocytosis. This case report describes how a multidisciplinary team (MDT) worked together to balance the mental and physical health needs of a patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
